Literature DB >> 28570733

Results of a Randomized Clinical Trial of Aflibercept vs Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Is It Time to Retire Your Laser?

Adam R Glassman1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28570733     DOI: 10.1001/jamaophthalmol.2017.1652

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  3 in total

1.  Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.

Authors:  Susan B Bressler; Wesley T Beaulieu; Adam R Glassman; Jeffrey G Gross; Michele Melia; Eric Chen; Michael R Pavlica; Lee M Jampol
Journal:  Ophthalmology       Date:  2018-07-03       Impact factor: 12.079

2.  Difference in the Vitreal Protein Profiles of Patients with Proliferative Diabetic Retinopathy with and without Intravitreal Conbercept Injection.

Authors:  Chen Zou; Minjie Zhao; Jingjing Yu; Dandan Zhu; Yunzhi Wang; Xinping She; Yanan Hu; Zhi Zheng
Journal:  J Ophthalmol       Date:  2018-04-19       Impact factor: 1.909

3.  Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept.

Authors:  Hye Kyoung Hong; Young Joo Park; Duk Ki Kim; Na-Kyung Ryoo; You-Jin Ko; Kyu Hyung Park; Ho Min Kim; Se Joon Woo
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-11-02       Impact factor: 4.799

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.